TARACTAN
LOE ApproachingNDAORALCONCENTRATE
Approved
Jun 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TARACTAN is an oral concentrate small-molecule drug approved in 1967 by Roche with unknown mechanism of action and indication profile. The drug's mechanism of action and specific therapeutic uses are not documented in available data. Patient population and clinical application cannot be determined without additional pharmacological information.
LOE Approaching
Product is in LOE-approaching phase with moderate competitive pressure (30), indicating shrinking commercial opportunities and potential team downsizing or portfolio transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TARACTAN currently has zero linked job openings, reflecting its LOE-approaching status and minimal hiring activity. Career opportunities on this product are limited to retention, legacy management, and transition roles rather than growth positions.
Brand ManagerProduct Manager
Worked on TARACTAN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.